Articles published by Cybin Inc.
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
October 01, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
September 24, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin Provides Corporate Update on Upcoming Clinical Milestones
September 19, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin Announces Completion of Previously Announced Share Consolidation
September 19, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
August 27, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
August 08, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
June 19, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
June 11, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
April 18, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
March 15, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
February 07, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
January 23, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
January 08, 2024
From Cybin Inc.
Via Business Wire
Tickers
CYBN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.